precisionmedicineonline42m
Aptadir Therapeutics Launches With $1.6M to Advance RNA Inhibitors for Cancers, Genetic Conditions
The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.
precisionmedicineonline59m
Bluebird Bio to Lay off 25 Percent of Workforce Amid Restructuring Effort
The company said it expects this restructuring plan to result in its quarterly cash flow breaking even by the second half of next year.
precisionmedicineonline3h
Genetic Counselors Can Help Patients Sort Concerns, Set Expectations for Gene Therapies
During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.
precisionmedicineonline20h
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
precisionmedicineonline22h
Astellas' Vyloy Approved in Europe as First-Line Treatment for CLDN18.2-Positive Gastric Cancer
The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.